Nasdaq
$7.20▼ 1.50%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $464.6MShares out 64.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 9.28After-hours26.09.29 05:03S-8Offering#●●●
ARVINAS, INC.
Arvinas, Inc. has filed a Form S-8 registration statement to issue a total of 107,154 shares of common stock as an inducement grant for a new employee. The issuance consists of 64,766 shares under a stock option award and 42,388 shares under a restricted stock unit (RSU) award, in accordance with Nasdaq Listing Rule 5635(c)(4).…more
$7.20-1.50%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22After-hours26.09.23 05:36144Ownership
ARVINAS, INC.
Sunil Agarwal of Arvinas, Inc. has filed an SEC Form 144 to report a proposed sale of company shares. This is a standard filing disclosing an insider's plan to dispose of their holdings.…more
$7.20-1.50%vs prev closeView filingShare - 9.9After-hours26.09.10 05:16144Ownership
ARVINAS, INC.
Noah Berkowitz, an executive at Arvinas, Inc., has filed a Form 144 to report a proposed sale of company shares. This is a standard notification regarding an insider's plan to dispose of their holdings.…more
$7.20-1.50%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 20:00#●●●#●●●
Arvinas Shares Positive Phase 1 Data for Parkinson’s Candidate ARV-102
Arvinas reported improvements in oculomotor function and biomarkers from its Phase 1 trial of ARV-102 for Parkinson's disease. These exploratory findings support further clinical evaluation of the candidate as a potential therapeutic approach.…more
$7.20-1.50%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1After-hours26.10.02 05:02
●●●●●●●● ●●●●● ●●●●●●
Arvinas announced it will present biomarker data from its Phase 1 clinical trial of ARV-102 at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. The drug candidate is an orally bioavailable protein degrader designed to target LRRK2 in patients with Parkinson’s disease.…more
$7.20-1.50%vs prev closeShareBenzinga - 9.29After-hours26.09.30 05:01
●●●●●●●● ●●●●● ●●●●●●
Arvinas announced the grant of stock options and restricted stock units (RSUs) to a newly hired employee in accordance with Nasdaq listing rules. This is a standard compensation package for talent acquisition and does not represent a material change in the company's financial or operational status.…more
$7.20-1.50%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report